Chris Mason MD, PhD, FRCS #3
Chris Mason is Professor of Regenerative Medicine Bioprocessing in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapies. He has a multidisciplinary track record spanning discovery, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and business. He holds a Clinical Sciences degree from Imperial College London, an MD from the United Medical & Dental Schools of Guy’s & St. Thomas’s Hospitals (now King’s College London) and a PhD in tissue-engineering bioprocessing from University College London. Chris specialized in surgery and is a Fellow of the Royal College of Surgeons both of England and in Ireland. Current appointments include; Chair of the BioIndustry Association (BIA) Regenerative Medicine & Cell Therapy Advisory Committee, Senior Editor of "Regenerative Medicine" journal, Co-founder and CEO of the London Regenerative Medicine Network, Trustee of the UK Stem Cell Foundation and of the British Neurological Research Trust and Co-Chair of the Alliance for Regenerative Medicine Cell Therapy Section. He sits on a number of national funding committees including BIRAX (Britain-Israel Research and Academic Exchange Partnership), Canada Foundation for Innovation (CFI) and Networks of Centres of Excellence of Canada (NCE).
Chris is on many national and international committees, working groups and initiatives related to the academic, clinical and commercial advancement of cell therapy including; Regenerative Medicine Expert Group (UK government policy advisory group), UK-Israel Science Council, International Expert Advisory Panel of the Canadian Stem Cell Foundation, ISSCR Industry Committee, ARM Communication & Education and Science & Technology Committees, ISCT Commercialization Committee, and United States Pharmacopeia (USP) Monographs - Biologics & Biotechnology Expert Committee. He is on the Advisory Panel of the Cell Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialisation of Regenerative Medicine (CCRM) and also advises a number of industry organisations including big pharma. Chris is a general spokesperson for the sector including frequent newspaper, radio and TV interviews plus social media via Twitter @Prof_ChrisMason.